Cato Research Partners with BioClinica
-- CRO Selects CTMS Solution for Global Complex Clinical Trial Support --
NEWTOWN, Pa., Nov 01, 2010 (BUSINESS WIRE) -- BioClinica(R), Inc., a global provider of clinical trial management solutions, today announced a new agreement with Cato Research Ltd., a full-service contract research organization. Cato Research selected BioClinica's clinical trial management system (CTMS) platform in its search for a best-in-class solution to better serve its growing worldwide client base.
"After an extensive product search, we were impressed with BioClinica's technology and the efficiencies that technology will create for both Cato Research employees and our clients," said Dr. Allen Cato, President of Cato Research. "One of our specialties is supporting multifaceted development programs that require innovative regulatory and clinical strategies. BioClinica's CTMS will assist us in this by helping us streamline our workflow and facilitate the clinical study processes."
"BioClinica is pleased to be selected by Cato Research for its clinical trial management needs after such an in-depth selection process," said Peter Benton, President of BioClinica's eClinical division. "We have seen a significant increase in customer interest in our CTMS solutions because these solutions provide the scalability needed to support global research and the flexibility sponsors need to create more efficient eClinical environments."
CTMS applications help to manage business and operational processes for clinical trials by capturing and manipulating the trial data electronically. BioClinica's CTMS capabilities include applications to manage data related to clinical sites, personnel, subjects, and clinical supplies; scheduling, tracking, and monitoring performance; site payments; study document management; vendors; and more. BioClinica Office-Smart Clinical Trial Manager (Office-Smart CTMS) is supported by Microsoft SharePoint and BioClinica technologies to provide superior team collaboration, connectivity, and efficiency in a multisite environment; it is the only CTMS capable of fully utilizing the Microsoft Office environment. With its ClinBUS Connector, BioClinica's CTMS interfaces with a variety of systems, such as electronic data capture and interactive voice or web response systems, to allow full integration of all clinical data.
"Office-Smart CTMS is an important facet of BioClinica's vision of a next-generation eClinical platform," said Mark Weinstein, CEO of BioClinica. "Our customers told us that improved CTMS functionality was a critical part of their strategy to connect information across their trials and improve overall efficiency. We believe BioClinica CTMS is the best available solution supporting those requirements."
Follow BioClinica on the Trial Blazers blog at http://info.bioclinica.com/blog, and on twitter at http://twitter.com/bioclinica.
Follow Cato Research on the Ask Cato blog at http://www.ask-cato.com, and on twitter at http://twitter.com/catoresearch.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management services. BioClinica supports pharmaceutical and medical device innovation with imaging core laboratory, internet image transport, electronic data capture, interactive voice and web response, and clinical supply chain design and optimization solutions. BioClinica services maximize efficiency and manageability throughout all phases of the clinical trial process. With more than 20 years of experience and over 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early-phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core laboratories on two continents and supports worldwide eClinical and data management services from offices in the United States, Europe, and Asia. For more information, please visit www.bioclinica.com.
About Cato Research
Cato Research is a midsize, full-service contract research and development organization with more than 20 years of experience as a provider of high-quality clinical trial services in a multitude of therapeutic areas to pharmaceutical, biotechnology, and medical device companies internationally. Specializing in complex development programs requiring innovative and creative regulatory and clinical strategies, Cato Research is recognized for its outstanding ability to provide the flexibility and responsiveness desired by sponsors. With a pivotal role in numerous marketing approvals, Cato Research consistently implements and conducts successful clinical trials and development programs. Headquartered at the Research Triangle Park in Durham, NC, Cato Research has 11 strategic locations worldwide, and its reach extends to clinical trials around the globe. For more information, please visit www.cato.com.
Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the companies' statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions; the timing of projects due to the variability in size, scope, and duration of projects; estimates and guidance made by management with respect to the companies' financial results, backlog, critical accounting policies, regulatory delays, and clinical study results that lead to reductions or cancellations of projects; and other factors, including general economic conditions and regulatory developments, not within the companies' control. The factors discussed herein and expressed from time to time in the companies' filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release, and the company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the companies' filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.
SOURCE: BioClinica, Inc.
Jim Dorsey, 267-757-3040
Diccicco Battista Communications
Beth Nestlerode, 484-342-3600
Porter, LeVay & Rose, Inc.
Linda Decker, 212-564-4700
Porter, LeVay & Rose, Inc.
Bill Gordon, 212-564-4700